Defining new frontiers of science to lead the future of RNA medicines
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. We are building a first-in-kind platform that integrates a critical mass of both established and emerging technologies and delivery mechanisms.
With this access to state-of-the-art RNA and novel delivery technologies, Orbital aims to advance an expansive and transformational portfolio of RNA therapeutics across a range of human diseases, including in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine.
The future of RNA medicines is today.
Leadership & Board
Scientific Co-Founders

Howard Chang, MD, PhD
Professor of Cancer Research and Professor of Genetics, Stanford University

Ravi Majeti, MD, PhD
Professor of Medicine, Chief of Division of Hematology Stanford University

Drew Weissman, MD, PhD
Professor in Vaccine Research, Perelman School of Medicine University of Pennsylvania

Gene Yeo, PhD, MBA
Professor of Cellular and Molecular Medicine, UC San Diego
Careers
Orbital Therapeutics is unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible!
The combination of high caliber science, revolutionary technologies, a world class team and an extraordinary team environment, positions Orbital to be a therapeutically transformational company.
We are creating a team of exceptional individuals for Automation, Bioinformatics, Platform Enhancement, and Protein Engineering & Structural Biology, who share a passion for innovation, collaboration and changing patients’ lives.